Abstract:OBJECTIVE:To investigate the clinical value of 18F-fluorodeoxyglucose (18F-FDG) coincidence SPECT imaging versus computed tomography (CT) for malignant lymphoma in the initial staging, early response to therapy, evaluation after completion of therapy and long-term follow-up.METHODS:18F-FDG SPECT scans was performed on 61 patients with pathologically proven malignant lymphoma. The mean age of this series was 55 years ranged from 12 to 85 years. The data of these patients were retrospectively analyzed, and the result of 18F-FDG SPECT scan was compared with the CT imaging result performed within 2 weeks before or after FDG scan. 161 18F-FDG SPECT scans were performed for initial tumor staging (n=61), early response to therapy (n=42), evaluation after completion of therapy (n=26) and long-term follow-up (n=32). Each patient had a follow-up >6 months.RESULTS:(1) Compared with CT scan, 18F-FDG SPECT imaging accurately upstaged the disease for 34.4% (21/61) of these patients at initial staging. It detected the lesions which were undetected by CT including bone marrow infiltration (n=17), foci of lymph node (n=3) and liver involvement (n=1). However, 3 patients were incorrectly staged, either downstaged or upstaged by 18F-FDG SPECT imaging. Of 212 lesions in 61 patients, 18-FDG SPECT imaging detected more lesions than CT (P < 0.01). The correspondence rate of '18-FDG SPECT imaging with marrow histology was 80.3% (49/61). (2) In early evaluation of the response to treatment, the accuracy, positive predictive value and negative predictive value of 18F-FDG SPECT imaging was 85.7%, 92.0% and 76.5% respectively, which is much higher than that of CT (64.3%, 75.0% and 50.0%), therefore, the therapeutic scheme in 21.4% (9/42) of these patients was changed by 18F-FDG SPECT imaging. Of 17 cases with negative 18F-FDG SPECT scan in early evaluation of therapy, clinical remission (13 complete remission and 3 partial remission) were achieved in 16 patients. Of the 25 patients with positive ones, 13 were considered as having progressive disease. (3) In the evaluation at the end of therapy or during follow-up, 58 18F-FDG SPECT imagings were performed in 26 patients. The specificity and positive predictive value were 85.7% and 68.4% versus 59.5% and 43.3%, respectively, by CT scan. Of 14 patients with residual masses detected by CT scan, 8 were diagnosed as complete remission (CR) by 18F-FDG SPECT imaging based on persistently negative FDG scans; The other 6 were interpreted as CR (n=1), partial remission (PR, n=2), non-remission (n=1) and progressive disease (n=2), thus there was only one false-positive FDG scan in these 14 patients.CONCLUSION:18F-FDG imaging is quite effective and superior to CT scan for malignant lymphoma in initial staging, evaluation of early response to therapy and after completion of therapy, and long-term follow-up, especially for evaluating the residual masse.

Relationship between 18F-lfuorodeoxyglucose PET/CT and diffusion weighted imaging in primary central nervous ;system lymphoma

18F-FDG PET/CT in Immunocompetent Patients with Primary Central Nervous System Lymphoma: Differentiation from Glioblastoma and Correlation with DWI.

FDG-PET in immunocompetent patients with primary central nervous system lymphoma: differentiation from GBM and correlation with DWI

Application of 18F-FDG PET-CT in differential diagnosis of gastrointestinal lymphoma from other types of tumors

[The Clinical Application of 18F-Fluorodeoxyglucose Coincidence Imaging in Lymphoma].

Diagnostic Value of Using 18F-FDG PET and PET/CT in Immunocompetent Patients with Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis

Quantitative Evaluation of Diffusion and Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Differentiation Between Primary Central Nervous System Lymphoma and Glioblastoma

The value of dual time-point fluorine-18 fluorodeoxyglucose PET/computed tomography imaging in predicting lymph node metastasis in non-small cell lung cancer patients

Correlative Investigation of Dynamic Contrast CT and Positron Emission Tomography with 18-Fluorodeoxy Glucose Standardized Uptake Value in Non-Small Cell Lung Cancer

Correlation of the apparent diffusion coefficient (ADC) and standardized uptake values (SUV) with overall survival in patients with primary non-small cell lung cancer (NSCLC) using 18F-FDG PET/MRI

Comparison of 18F-FDG Coincidence SPECT Imaging and Computed Tomography in the Initial Staging and Therapeutic Evaluation of Lymphomas

Differentiating Primary Central Nervous System Lymphomas From Glioblastomas and Inflammatory Demyelinating Pseudotumor Using Relative Minimum Apparent Diffusion Coefficients.

The Role Of 18F-FDG PET/CT In Evaluation Of Primary CNS Lymphoma: The Path Less Travelled

Multiparametric differentiation of intracranial central nervous system lymphoma and high-grade glioma using diffusion-, perfusion-, susceptibility-weighted magnetic resonance imaging, and spectroscopy

Value of Pretherapeutic DWI in Evaluating Prognosis and Therapeutic Effect in Immunocompetent Patients with Primary Central Nervous System Lymphoma Given High-Dose Methotrexate-Based Chemotherapy: ADC-based Assessment

The Prognostic Significance of Pontine-White Matter Score in Primary Central Nervous System Lymphoma Patients

Application effect of 18F-FDG PET/CT technique in diagnosis and prognosis evaluation of lymphoma

Functional imaging in head and neck squamous cell carcinoma: correlation of PET/CT and diffusion-weighted imaging at 3 Tesla

Correlation Analysis of Pre-Therapy FDG-PET/CT with Prognosis in Patients with Diffuse Large B-cell Lymphoma

Correlation of apparent diffusion coefficients measured by 3T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer

Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma